Osborne Clarke advises Amphista Therapeutics on its $53M Series B funding round
International legal practice Osborne Clarke has advised Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, on...
Published on
18/03/2021
Read time
1m